The Federal Drug Administration delayed review of a Takeda Pharmaceuticals drug that is combined with Actos, a diabetes medication that has been linked to bladder cancer. Actos was approved by the FDA in 1999 but recently was determined to be harmful.
Takeda, headquartered in Japan, boasted Actos as a safe alternative to other diabetes medications that caused strokes and heart attacks. The reports say the drug will start to give patients bladder cancer in as little as 12 months.
“Actos is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer,” the US Drug Watchdog said in a released statement. “Actos side effects include increased risk of congestive heart failure, and an increased risk for bladder cancer.”
Lawsuits were first filed against Takeda in August 2011. Have you or a loved one been injured or killed due to a defective product or medication?
Wooten, Kimbrough & Normand, P.A.—Orlando personal injury attorneys.
Be aware of drugs that potentiate diabetes.
Eli Lilly Zyprexa Olanzapine issues linger.
The use of powerful antipsychotic drugs has increased in children as young as three years old. Weight gain, increases in triglyceride levels and associated risks for diabetes and cardiovascular disease. The average weight gain (adults) over the 12 week study period was the highest for Zyprexa—17 pounds. You’d be hard pressed to gain that kind of weight sport-eating your way through the holidays.One in 145 adults died in clinical trials of those taking the antipsychotic drug Zyprexa.
This was Lilly's #1 product $5 billion per year sales,moreover Lilly also make billions more on drugs that treat diabetes.
--- Daniel Haszard Zyprexa activist and patient.
NOTE-Eli Lilly also co-markets Actos
Comments for this article are closed.